Daridorexant

7 trials 4 recruiting NNeurology/Psychiatry

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

4 Recruiting

2 Completed trials

6 Sponsors

7 Countries

Phase III

Phase II

Phase IV

Phase III: 1 Phase II: 2 Phase IV: 4

Indications tested

Insomnia 1 Nocturia 1

Sponsors using this IMP

Idorsia Pharmaceuticals Ltd. 2 Centre Hospitalier Universitaire De Nantes 1 Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL 1 Linkopings Universitet 1 Region Midtjylland 1 Universita' Degli Studi Di Roma Tor Vergata 1

All trials

7 total

Study evaluating the efficacy and safety of daridorexant in patients with major depressive disorder and insomnia. Pending

2025-524794-16-00 Phase IV 1 country Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL
Daridorexant treatment in adolescents with enuresis. Recruiting

2025-521443-20-00 Phase III 1 country Region Midtjylland
DARIdorexant efficacy on the COGnitive performance in patients with chronic insomnia disorder. DARI-COG Study Recruiting

2024-517768-52-00 Phase IV 1 country Universita' Degli Studi Di Roma Tor Vergata
The dual orexin receptor antagonist daridorexant as an adjunct to improve buprenorphine maintenance therapy of opioid use disorder Recruiting

2024-517482-16-00 Phase II 1 country Linkopings Universitet
Daridorexant to treat insomnia in patients with mild cognitive impairment and mild to moderate Alzheimer disease. Recruiting

2023-503301-10-00 Phase IV 1 country Centre Hospitalier Universitaire De Montpellier
A study to find out if daridorexant is safe and efficacious to treat insomnia in patients with insomnia and comorbid nocturia Ended

2022-501246-30-00 Phase IV 2 countries Idorsia Pharmaceuticals Ltd.
A study to find out which dose of daridorexant is safe and effective to treat insomnia in children and adolescents 10 to <18 years old Ended

2024-513885-20-00 Phase II 4 countries Idorsia Pharmaceuticals Ltd.

Showing 1–7 of 7 trials

← All drugs A–Z